Angiotensin II Receptor Blocker And Neprilysin Inhibitor Sacubitril/valsartan Attenuates Experimental Pulmonary Hypertension

被引：0
|
作者：
Clements, Richard T.
Vang, Alexander
Kue, Nouaying R.
Mancini, Thomas
Morrison, Alan R.
McCullough, Danielle J.
Mallem, Krishna
Choudhary, Gaurav
机构：
来源：
CIRCULATION | 2019年 / 140卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A17134
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan
    Clements, Richard T.
    Vang, Alexander
    Fernandez-Nicolas, Ana
    Kue, Nouaying R.
    Mancini, Thomas J.
    Morrison, Alan R.
    Mallem, Krishna
    McCullough, Danielle J.
    Choudhary, Gaurav
    CIRCULATION-HEART FAILURE, 2019, 12 (11)
  • [2] Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan)
    Petramala, Luigi
    Letizia, Claudio
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (04) : 252 - 252
  • [3] The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
    Javad Habibi
    Annayya R. Aroor
    Nitin A. Das
    Camila M. Manrique-Acevedo
    Megan S. Johnson
    Melvin R. Hayden
    Ravi Nistala
    Charles Wiedmeyer
    Bysani Chandrasekar
    Vincent G. DeMarco
    Cardiovascular Diabetology, 18
  • [4] The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
    Habibi, Javad
    Aroor, Annayya R.
    Das, Nitin A.
    Manrique-Acevedo, Camila M.
    Johnson, Megan S.
    Hayden, Melvin R.
    Nistala, Ravi
    Wiedmeyer, Charles
    Chandrasekar, Bysani
    DeMarco, Vincent G.
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
  • [5] Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
    Dargad, Ramesh R.
    Prajapati, Mahesh R.
    Dargad, Rohit R.
    Parekh, Jai D.
    INDIAN HEART JOURNAL, 2018, 70 : S102 - S110
  • [6] Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
    Acanfora, Domenico
    Ciccone, Marco Matteo
    Scicchitano, Pietro
    Acanfora, Chiara
    Casucci, Gerardo
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (03) : 135 - 136
  • [7] Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril plus valsartan: A pharmacovigilance study
    Guion-Firmin, Julia
    Tessier, Samuel
    Lepelley, Marion
    Faillie, Jean-Luc
    Montastruc, Jean-Louis
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 (02) : 378 - 389
  • [8] Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
    Seki, Takunori
    Goto, Kenichi
    Kansui, Yasuo
    Ohtsubo, Toshio
    Matsumura, Kiyoshi
    Kitazono, Takanari
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (10):
  • [9] Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity
    Boutagy, Nabil E.
    Feher, Attila
    Pfau, Daniel
    Liu, Zhao
    Guerrera, Nicole M.
    Freeburg, Lisa A.
    Womack, Sydney J.
    Hoenes, Abigail C.
    Zeiss, Caroline
    Young, Lawrence H.
    Spinale, Francis G.
    Sinusas, Albert J.
    JACC: CARDIOONCOLOGY, 2020, 2 (05): : 774 - 787
  • [10] The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond
    Kazuomi Kario
    Current Cardiology Reports, 2018, 20
12345